Relay Therapeutics (RLAY) Consolidated Net Income (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Consolidated Net Income data on file, last reported at -$73.2 million in Q1 2026.

• Quarterly Consolidated Net Income rose 4.95% year-over-year to -$73.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$271.9 million (up 18.44% YoY) and the FY2025 annual result came in at -$275.7 million, up 18.36% from the prior year.
• Consolidated Net Income retreated to -$73.2 million in Q1 2026 per RLAY's latest filing, from -$54.9 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$54.9 million in Q4 2025 and bottomed at -$98.5 million in Q2 2023.
• The 5-year median for Consolidated Net Income is -$76.8 million (2022), against an average of -$77.6 million.
• The widest annual swing landed in 2022, when Consolidated Net Income soared 60.29%; it then sank 51.89% in 2023.
• Tracing RLAY's Consolidated Net Income over 5 years: stood at -$67.5 million in 2022, then dropped by 23.74% to -$83.5 million in 2023, then grew by 8.97% to -$76.0 million in 2024, then rose by 27.74% to -$54.9 million in 2025, then plunged by 33.35% to -$73.2 million in 2026.
• Per Business Quant, the three latest RLAY Consolidated Net Income figures stand at -$73.2 million (Q1 2026), -$54.9 million (Q4 2025), and -$74.0 million (Q3 2025).

Peer Comparison